Bookmark and Share
SMR000310192 (CID 16193817) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(31)
 
 
Inactive(654)
 
 
Inconclusive(14)
 
 
Unspecified(3)
 
 
Top Targets:
7tm 4(39)
 
 
 
Abhydrolase 2(21)
 
 
 
 
Esterase lipa..(16)
 
 
G-alpha(8)
 
 
 
Peptidase S9(7)
 
 
BioAssay Types:
Screening(427)
 
 
 
 
Confirmatory(194)
 
 
 
 
 
Literature(11)
 
 
BioActivity Types:
Potency(133)
 
 
 
 
 
IC50(42)
 
 
 
 
EC50(7)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 582    Data Row: 702   Total Pages: 36   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID160654496]
0.144Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP [AID651990_2, Type: confirmatory]acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
View
2
[SID160654496]
Average IC50 [LYPLA2] 0.51Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Substrate-based fluorescence-based biochemical determination of kinetic parameters [AID652001, Type: confirmatory]
View
3
[SID24812860]
Potency 10qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) [AID651820, Type: confirmatory]
View
4
[SID24812860]
Potency 12.9953qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
5
[SID24812860]
EC50 50A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen [AID2252, Type: confirmatory]
View
6
[SID24812860]
Counterscreen for antagonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify nonselective antagonists [AID651780, Type: screening]guanine nucleotide-binding protein subunit alpha-15 [Homo sapiens] [gi:156104883]
View
7
[SID92709328]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID652030, Type: other]
View
8
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situ [AID651980, Type: other]
View
9
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID651988, Type: other]
View
10
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in vivo [AID651985, Type: other]
View
11
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in situ [AID651986, Type: other]
View
12
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess binding mode [AID651987, Type: other]
View
13
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP [AID651990, Type: confirmatory]
View
14
[SID160654495]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro [AID651981, Type: other]
View
15
[SID24812860]
Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1 [AID1304, Type: screening]neuropeptide Y receptor type 1 [Homo sapiens] [gi:4505445]
View
16
[SID24812860]
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1) [AID624466, Type: screening]trace amine-associated receptor 1 [Homo sapiens] [gi:21264324]
View
17
[SID24812860]
Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2 [AID1359, Type: screening]neuropeptide Y receptor type 2 [Homo sapiens] [gi:4505447]
View
18
[SID24812860]
Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide [AID687016, Type: screening]E3 ubiquitin-protein ligase UHRF1 isoform 1 [Homo sapiens] [gi:115430235]
View
19
[SID92709328]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity [AID652030_2, Type: other]lysophospholipase 2 [Mus musculus] [gi:123122209]
View
20
[SID160654496]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in vivo [AID651985_2, Type: other]lysophospholipase 2 [Mus musculus] [gi:123122209]
View